Taken together, our results revealed that inhibiting Zbtb16 might be able to decrease AF risk through downregulating Txnip-Trx2 signaling, which provided a novel therapeutic target for AF in the setting of T2DM. Here, TXNIP is linked to type 2 diabetes mellitus.